Back to News
Market Impact: 0.4
Xenetic To Acquire Santersus In All-Stock Deal To Advance NET-Focused Pipeline
Source: Nasdaq
M&A & RestructuringHealthcare & BiotechCompany Fundamentals
Xenetic Biosciences and Swiss medical-device company Santersus AG signed a definitive share-exchange agreement to combine their NET-targeting technologies. The transaction is intended to create a Nasdaq-listed, clinical-stage company focused on diseases driven by neutrophils, potentially broadening Xenetic's development platform and investor access.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
XBIO0.55
More News
- Binance seeks to shore up confidence after record $6.3 billion heist
- Why is Alstom stock down 27% today?
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Alstom shares sink 28% after outlook cut on Coradia Max execution issues
- Kosmos Energy stock sinks on third quarter earnings, revenue miss
- NUBURU Completes Tekne Acquisition, Adding a $93 Million Defense & Dual-Use Program Portfolio and Advancing Expansion Across NATO and Allied Markets